US EditionAfter US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen
- Japan's health ministry has approved Leqembi, a drug for Alzheimer's disease, making it the first country with a rapidly aging population to have a treatment for the disease.
- Leqembi, developed by Japanese drugmaker Eisai Co. And US biotechnology firm Biogen Inc., is designed for patients in the early stages of Alzheimer's, helping to slow their cognitive decline. The approval was announced by Prime Minister Fumio Kishida.
- The number of dementia patients aged 65 or older in Japan is expected to rise to 7 million by 2025, highlighting the urgent need for treatments like Leqembi. Eisai Co. Is dedicated to providing this new treatment to individuals and their families.
Insights by Ground AI
Does this summary seem wrong?
29 Articles
29 Articles
All
Left
8
Center
9
Right
4
After US approval, Japan OKs Leqembi, its first Alzheimer's drug, developed by Eisai and Biogen
TOKYO (AP) -- Japan's health ministry has approved Leqembi, a drug for Alzheimer's disease that was jointly developed by Japanese and U.S. pharmaceutical companies. It's the first drug for treatment of the disease in a country with a rapidly aging population.
·Canada
Read Full Article
After US approval, Japan OKs Leqembi, its first Alzheimer's drug, developed by Eisai and Biogen
TOKYO (AP) -- Japan's health ministry has approved Leqembi, a drug for Alzheimer's disease that was jointly developed by Japanese and U.S. pharmaceutical companies. It's the first drug for treatment of the disease in a country with a rapidly aging population.
·Canada
Read Full Article
Coverage Details
Total News Sources29
Leaning Left8Leaning Right4Center9Last UpdatedBias Distribution43% Center
Bias Distribution
- 43% of the sources are Center
43% Center
L 38%
C 43%
R 19%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
